PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib
This study evaluated the most effective timing for anlotinib to downregulate PD-L1 expression in tumor and normal tissues to promote immune infiltration. Our findings may offer valuable insights for the clinical use of anlotinib and its potential side effects.
Authors
- Yingfang Feng (ORCID: https://orcid.org/0000-0002-5034-8879)
- Tingting Qin (ORCID: https://orcid.org/0000-0002-1975-9696)
- Shaochuan Liu (ORCID: https://orcid.org/0000-0002-4305-6173)
- Yuan Gao (ORCID: https://orcid.org/0000-0001-8610-7981)
- Jing Wang (ORCID: https://orcid.org/0000-0002-7501-8702)
- Kai Li (ORCID: https://orcid.org/0000-0002-0810-2437)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-4835-8541)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Tianjin haihe hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.3389/fonc.2025.1544278
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00